PFIZER INC (PFE) — SEC Filings

Latest SEC filings for PFIZER INC (PFE), explained in plain English.

Sentiment Overview: 1 bearish, 48 neutral, 1 mixed

Recent Filings (50)

• 8-K Filing — 8-K · 2025-12-16T00:00:00.000Z [neutral]
• Pfizer Issues Multiple Note Series — 8-K · 2025-11-21T00:00:00.000Z [neutral] Risk: low
  On November 18, 2025, Pfizer Inc. filed an 8-K report detailing the issuance of several series of notes. These include $1.000 Notes due 2027, $2.875 Notes due 2
• 13F-HR Filing — 13F-HR · 2025-11-13T00:00:00.000Z [neutral]
• Pfizer Q3 Revenue Dips 6% Amid R&D Surge, Net Income Down 21% — 10-Q · 2025-11-04T00:00:00.000Z [mixed] Risk: medium
  Pfizer Inc. reported a decrease in total revenues for the three months ended September 28, 2025, falling to $16.654 billion from $17.702 billion in the prior ye
• 13F-HR Filing — 13F-HR · 2025-08-11T00:00:00.000Z [neutral]
• Pfizer Q2 Revenue Dips 12% Amid Product Sales Decline — 10-Q · 2025-08-05T00:00:00.000Z [bearish] Risk: medium
  Pfizer Inc. reported product revenue of $12.5 billion for the second quarter of 2025, a decrease from $14.2 billion in the second quarter of 2024, representing
• Pfizer Inc. Files 8-K Report — 8-K · 2025-05-19T00:00:00.000Z [neutral] Risk: low
  On May 14, 2025, Pfizer Inc. filed an 8-K report detailing other events and financial statements. The filing does not disclose specific new material events or f
• 13F-HR Filing — 13F-HR · 2025-05-13T00:00:00.000Z [neutral]
• Pfizer Files Q1 2025 10-Q Report — 10-Q · 2025-05-05T00:00:00.000Z [neutral] Risk: low
  Pfizer Inc. filed its 10-Q for the period ending March 30, 2025. The filing details financial performance and operational updates for the first quarter of 2025.
• Pfizer Inc. Files 8-K on Financials and Operations — 8-K · 2025-04-29T00:00:00.000Z [neutral] Risk: low
  On April 29, 2025, Pfizer Inc. filed an 8-K report detailing results of operations and financial condition. The filing also covers cost associated with exit or
• Pfizer Inc. Files 8-K on Shareholder Votes — 8-K · 2025-04-28T00:00:00.000Z [neutral] Risk: low
  Pfizer Inc. filed an 8-K on April 28, 2025, reporting on matters submitted to a vote of security holders as of April 24, 2025. The filing details the company's
• Pfizer Inc. Files Proxy Materials — DEFA14A · 2025-04-11T00:00:00.000Z [neutral] Risk: low
  Pfizer Inc. filed a Definitive Additional Materials proxy statement (DEFA14A) on April 11, 2025. The filing is related to the company's solicitation of proxies
• Pfizer Files Supplemental Proxy Materials — DEFA14A · 2025-04-10T00:00:00.000Z [neutral] Risk: low
  Pfizer Inc. filed a Definitive Additional Materials proxy statement on April 10, 2025, indicating it sent a form of email to certain shareholders. This filing i
• Pfizer Files Supplemental Proxy Materials for 2025 — DEFA14A · 2025-04-07T00:00:00.000Z [neutral] Risk: low
  Pfizer Inc. filed a Definitive Additional Materials proxy statement on April 7, 2025, related to its 2025 shareholder engagement. This filing is supplemental to
• Pfizer's 2025 DEF 14A: Executive Pay & 2024 Financials — DEF 14A · 2025-03-13T00:00:00.000Z [neutral] Risk: low
  Pfizer Inc. filed its DEF 14A on March 13, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other corporate gov
• Pfizer Files 2024 10-K Report — 10-K · 2025-02-27T00:00:00.000Z [neutral] Risk: medium
  Pfizer Inc. filed its 2024 10-K report on February 27, 2025, detailing its financial performance for the fiscal year ending December 31, 2024. The company, head
• 13F-HR Filing — 13F-HR · 2025-02-14T00:00:00.000Z [neutral]
• Pfizer Inc. Files 8-K on Financials — 8-K · 2025-02-04T00:00:00.000Z [neutral] Risk: low
  On February 4, 2025, Pfizer Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statements and e
• Pfizer Inc. Files 8-K Report — 8-K · 2024-12-17T00:00:00.000Z [neutral] Risk: low
  On December 17, 2024, Pfizer Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD Disclosure. N
• Pfizer Files 10-Q for Q3 2024 — 10-Q · 2024-11-04T00:00:00.000Z [neutral] Risk: low
  Pfizer Inc. filed its 10-Q for the period ending September 29, 2024. The filing covers the third quarter and the first nine months of the fiscal year. Key finan
• Pfizer Inc. Files 8-K on Financials — 8-K · 2024-10-29T00:00:00.000Z [neutral] Risk: low
  On October 29, 2024, Pfizer Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on common stoc
• Pfizer Inc. Files 8-K: Board and Executive Compensation Updates — 8-K · 2024-10-15T00:00:00.000Z [neutral] Risk: low
  On October 10, 2024, Pfizer Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes information on
• Pfizer Files 13D/A Amendment for Haleon plc Holdings — SC 13D/A · 2024-10-03T00:00:00.000Z [neutral] Risk: medium
  Pfizer Inc. filed an amendment (10) to its Schedule 13D on October 3, 2024, regarding its holdings in Haleon plc. The filing details changes in beneficial owner
• Pfizer Amends Haleon Stake Filing — SC 13D/A · 2024-10-01T00:00:00.000Z [neutral] Risk: medium
  Pfizer Inc. filed an amendment (No. 9) to its Schedule 13D on October 1, 2024, regarding its holdings in Haleon plc. The filing indicates a change in the benefi
• Pfizer Inc. Files 10-Q for Q2 2024 — 10-Q · 2024-08-05T00:00:00.000Z [neutral] Risk: low
  Pfizer Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational segments for the second quarter and the
• Pfizer Inc. Files 8-K: Financial Update — 8-K · 2024-07-30T00:00:00.000Z [neutral] Risk: low
  On July 30, 2024, Pfizer Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statements and exhi
• Pfizer Updates Haleon Stake Filing — SC 13D/A · 2024-07-29T00:00:00.000Z [neutral] Risk: medium
  Pfizer Inc. filed an amendment (No. 8) to its Schedule 13D on July 29, 2024, regarding its holdings in Haleon plc. The filing indicates changes in beneficial ow
• Pfizer Announces Executive and Board Changes — 8-K · 2024-07-26T00:00:00.000Z [neutral] Risk: medium
  On July 24, 2024, Pfizer Inc. announced changes in its executive leadership and board of directors. Dr. Mikael Dolsten will transition from his role as Chief Sc
• Pfizer Adjusts Executive Compensation Plans — 8-K · 2024-07-10T00:00:00.000Z [neutral] Risk: low
  On July 9, 2024, Pfizer Inc. announced changes to its executive compensation program. The company's Compensation Committee of the Board of Directors approved am
• Pfizer Appoints New Directors, CAO Departs — 8-K · 2024-07-01T00:00:00.000Z [neutral] Risk: low
  On June 27, 2024, Pfizer Inc. filed an 8-K report detailing the departure of its Chief Accounting Officer, Michael G. McLellan, effective June 28, 2024. The com
• Pfizer Reports Exit and Disposal Costs — 8-K · 2024-05-22T00:00:00.000Z [neutral] Risk: medium
  On May 22, 2024, Pfizer Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing does not specify any dollar amounts or s
• Pfizer Files Q1 2024 10-Q Report — 10-Q · 2024-05-08T00:00:00.000Z [neutral] Risk: low
  Pfizer Inc. filed its 10-Q for the period ending March 31, 2024, reporting on its financial performance. The filing details various financial statements and dis
• Pfizer Inc. Files 8-K with Financial Updates — 8-K · 2024-05-01T00:00:00.000Z [neutral] Risk: low
  On May 1, 2024, Pfizer Inc. filed an 8-K report detailing its financial results and condition. The filing includes financial statements and exhibits, providing
• Pfizer Inc. Files 8-K on Shareholder Vote Matters — 8-K · 2024-04-29T00:00:00.000Z [neutral] Risk: low
  On April 25, 2024, Pfizer Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The filing does not contain specific details
• Pfizer Files Proxy Materials — DEFA14A · 2024-04-11T00:00:00.000Z [neutral] Risk: low
  Pfizer Inc. filed a Definitive Additional Materials proxy statement on April 11, 2024. This filing is related to the company's annual meeting and likely contain
• Pfizer Inc. Proxy Statement Reminder Filed — DEFA14A · 2024-04-09T00:00:00.000Z [neutral] Risk: low
  Pfizer Inc. filed a Definitive Additional Materials proxy statement (DEFA14A) on April 9, 2024. This filing serves as a reminder to shareholders regarding upcom
• Pfizer Files Proxy Supplement for 2024 Annual Meeting — DEFA14A · 2024-03-28T00:00:00.000Z [neutral] Risk: low
  Pfizer Inc. filed a Definitive Additional Materials proxy statement (DEFA14A) on March 28, 2024, supplementing its Notice of 2024 Annual Meeting. This filing is
• Pfizer Files 13D/A Amendment for Haleon plc — SC 13D/A · 2024-03-22T00:00:00.000Z [neutral] Risk: medium
  Pfizer Inc. filed an amendment (SC 13D/A) on March 22, 2024, regarding its holdings in Haleon plc. The filing indicates a change in the beneficial ownership of
• Pfizer Files 13D/A Amendment for Haleon plc — SC 13D/A · 2024-03-19T00:00:00.000Z [neutral] Risk: medium
  Pfizer Inc. filed an amendment (Amendment No. 6) to its Schedule 13D on March 19, 2024, regarding its holdings in Haleon plc. Pfizer previously held a significa
• SC 13G/A Filing — SC 13G/A · 2024-03-15T00:00:00.000Z [neutral]
• Pfizer Files 2023 Proxy Statement: Executive Compensation Details — DEF 14A · 2024-03-14T00:00:00.000Z [neutral] Risk: low
  Pfizer Inc. filed its DEF 14A proxy statement on March 14, 2024, for the fiscal year ending December 31, 2023. The filing details executive compensation, includ
• Pfizer Files 2023 10-K, Details Fiscal Year Performance — 10-K · 2024-02-22T00:00:00.000Z [neutral] Risk: medium
  Pfizer Inc. filed its 10-K on February 22, 2024, for the fiscal year ending December 31, 2023. The company, identified by CIK 0000078003, is a pharmaceutical pr
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• Vanguard Amends Pfizer Stake: SC 13G/A Filed Feb 13, 2024 — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral] Risk: low
  The Vanguard Group, a major investment firm, filed an amendment to its Schedule 13G on February 13, 2024, indicating its beneficial ownership of Pfizer Inc. com
• Pfizer Updates Registered Securities on NYSE — 8-K · 2024-01-30T00:00:00.000Z [neutral]
  Pfizer Inc. filed an 8-K on January 30, 2024, to update its registered securities, specifically its Common Stock ($0.05 par value) and 1.000% Notes due 2027. Bo
• State Street Corp Maintains Passive Stake in Pfizer Inc. — SC 13G/A · 2024-01-29T00:00:00.000Z [neutral]
  State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 29, 2024, disclosing its ownership of Pfizer Inc. common stock as
• Pfizer Amends 13D Filing on Longboard Pharmaceuticals Stake — SC 13D/A · 2024-01-29T00:00:00.000Z [neutral]
  Pfizer Inc. filed an Amendment No. 3 to its Schedule 13D on January 25, 2024, regarding its ownership in Longboard Pharmaceuticals, Inc. This filing updates pre
• BlackRock Amends Pfizer Stake: Ownership Update Filed — SC 13G/A · 2024-01-26T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, indicating a change in its ownership stake in Pfizer Inc. as of December 31, 2023. This amendment,
• Pfizer Updates Haleon Stake in SC 13D/A Amendment No. 5 — SC 13D/A · 2024-01-19T00:00:00.000Z [neutral]
  Pfizer Inc. filed an Amendment No. 5 to its Schedule 13D on January 19, 2024, regarding its ownership in Haleon plc. This filing updates previous disclosures ab
• Pfizer Confirms NYSE Listing for Common Stock, 1.000% Notes Due 2027 — 8-K · 2024-01-10T00:00:00.000Z [neutral]
  Pfizer Inc. filed an 8-K on January 10, 2024, to update its registered securities. The filing confirms that both its Common Stock, with a $.05 par value, and it